title: Modification of vimentin: a general mechanism of nonenzymatic glycation in human skin.
abstract: In a recent study, we were able to show that the intermediate filament protein vimentin aggregates in human dermal fibroblasts because of modification by the advanced glycation endproduct carboxymethyllysine (CML). In this work, we investigated the formation of intracellular CML in relation to the concentration of glucose in the culture medium. The natural degradation product of glucose, methylglyoxal, was able to induce the aggregation of vimentin. This dicarbonyl leads to the formation of the modifications MG-H1 and carboxyethyllysine (CEL) as a result of the reaction with arginine and lysine residues of proteins. Furthermore, we found that the protein vimentin was modified, not only by CML and CEL, but also by pentosidine and pyrraline. These findings underline the special position of vimentin as a preferential target of the Maillard reaction in human skin.
authors.affiliation: R & D, Beiersdorf AG, Hamburg, Germany. Thomas.Kueper@beiersdorf.com
authors.forename: Thomas
authors.initials: T
authors.lastname: Kueper
authors.forename: Tilman
authors.initials: T
authors.lastname: Grune
authors.forename: Gesa-Meike
authors.initials: GM
authors.lastname: Muhr
authors.forename: Holger
authors.initials: H
authors.lastname: Lenz
authors.forename: Klaus-Peter
authors.initials: KP
authors.lastname: Wittern
authors.forename: Horst
authors.initials: H
authors.lastname: Wenck
authors.forename: Franz
authors.initials: F
authors.lastname: Stäb
authors.forename: Thomas
authors.initials: T
authors.lastname: Blatt
mesh_terms: D001120:Arginine / Q000031:analogs & derivatives / Q000378:metabolism; D015153:Blotting, Western; D002478:Cells, Cultured; D005145:Face; D017127:Glycation End Products, Advanced / Q000378:metabolism* / Q000494:pharmacology; D006031:Glycosylation; D006037:Glyoxal / Q000494:pharmacology*; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives / Q000378:metabolism; D009646:Norleucine / Q000031:analogs & derivatives / Q000378:metabolism; D011758:Pyrroles / Q000378:metabolism; D011765:Pyruvaldehyde / Q000494:pharmacology*; D012867:Skin / Q000187:drug effects / Q000378:metabolism*; D014746:Vimentin / Q000302:isolation & purification / Q000378:metabolism*
chemical_list: D017127:Glycation End Products, Advanced; D011758:Pyrroles; D014746:Vimentin; D006037:Glyoxal; D011765:Pyruvaldehyde; C059571:2-formyl-5-(hydroxymethyl)pyrrole-1-norleucine; D009646:Norleucine; D001120:Arginine; C062187:pentosidine; D008239:Lysine